Johnson & Johnson to Present MEMBRANE Trial Analysis on Cognitive Outcomes After Brain Bleed Treatment

PUBT · 1d ago
Johnson & Johnson to Present MEMBRANE Trial Analysis on Cognitive Outcomes After Brain Bleed Treatment
  • Johnson & Johnson will present 13 neurovascular research abstracts, including four podium presentations, at SVIN 2026 in Las Vegas.
  • MEMBRANE trial analyses will examine cognitive outcomes, anesthesia approaches and healthcare resource use following embolization for chronic subdural hematoma.
  • Cognitive findings will be presented November 19; 12-month results for treatment with TRUFILL n-BCA are scheduled for November 20.
  • The EXCELLENT registry presentation on November 20 will examine ischemic stroke treatment outcomes and clot characteristics in 2,000 patients across three continents.
  • That prospective registry included first-line use of CEREGLIDE 71 and EMBOTRAP devices.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on November 17, 2026, and is solely responsible for the information contained therein.